VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy

Thrombosis Research
Fernanda A OrsiKaren E Weck


Warfarin-based anticoagulant therapy is associated with large variability in dose response. Genetic variability in the VKORC1 and CYP2C9 genes is associated with increased warfarin sensitivity. In addition, rare coding region mutations in VKORC1 have been associated with resistance to warfarin. VKORC1 and CYP2C9 variability associated with altered warfarin response is less well characterized in African and mixed-raced populations such as Brazilians. To determine genetic variability associated with altered warfarin response among Brazilian patients, sixty-two adult patients with extreme resistance or sensitivity to warfarin were genotyped for variants in CYP2C9 and VKORC1. Of the 51 patients on low doses of warfarin, the VKORC1--1639 (3673) G>A polymorphism associated with warfarin sensitivity was present in 48 (94.1%), including 97% of Caucasians, 82% of African-descent patients, and all 7 (100%) patients of Indian descent. Additionally, 52.9% of warfarin sensitive patients had at least one CYP2C9*2 or CYP2C9*3 decreased metabolism allele, 63.6% of Caucasians and 54% of African-descent patients. Of the 11 patients on high doses of warfarin, sequencing of VKORC1 revealed a nonsynonymous V66M mutation in two warfarin resistant pa...Continue Reading


Jan 1, 1988·European Journal of Clinical Pharmacology·O G NilsenE Thue
Jul 2, 2004·Clinical Pharmacology and Therapeutics·Rosane Vianna-JorgeGuilherme Suarez-Kurtz
Jun 3, 2005·The New England Journal of Medicine·Mark J RiederAllan E Rettie
Sep 9, 2006·Molecular Interventions·Allan E Rettie, Guoying Tai
Oct 25, 2006·Journal of Thrombosis and Haemostasis : JTH·R L D'AmbrosioM Margaglione
Dec 13, 2006·Thrombosis Research·Tong Yin, Toshiyuki Miyata
Oct 24, 2007·European Journal of Clinical Pharmacology·M V LimaR Vianna-Jorge
Feb 29, 2008·Clinical Pharmacology and Therapeutics·B F GageH L McLeod
Mar 7, 2008·The New England Journal of Medicine·Ute I SchwarzC Michael Stein
Apr 19, 2008·Journal of Thrombosis and Haemostasis : JTH·E B WilmsM Hermans
Aug 6, 2008·Journal of Thrombosis and Haemostasis : JTH·D J HarringtonA D Mumford
Aug 30, 2008·Clinical Pharmacology and Therapeutics·J A PeriniG Suarez-Kurtz
Nov 21, 2008·Pharmacogenomics·Jamila A PeriniGuilherme Suarez-Kurtz
Feb 21, 2009·The New England Journal of Medicine·UNKNOWN International Warfarin Pharmacogenetics ConsortiumJ A Johnson

❮ Previous
Next ❯


Jun 9, 2012·British Journal of Clinical Pharmacology·Guilherme Suarez-Kurtz, Mariana R Botton
Oct 28, 2014·Expert Opinion on Drug Metabolism & Toxicology·Guilherme Suarez-Kurtz, Mariana R Botton
Mar 19, 2019·Omics : a Journal of Integrative Biology·Arinao NdadzaCollet Dandara
May 26, 2018·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Joanna WzorekAnetta Undas
Aug 7, 2021·Molecular Diagnosis & Therapy·Thiago Dominguez Crespo HirataRosario Dominguez Crespo Hirata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.